||EPS - Basic
||Market Cap (m)
Real-Time news about Cytomyx Hldgs (London Stock Exchange): 0 recent articles
|Cytomyx Daily Update: Cytomyx Hldgs is listed in the Unknown sector of the London Stock Exchange with ticker CYX. The last closing price for Cytomyx was 1.10p.|
Cytomyx Hldgs has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 63,308,000 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Cytomyx Hldgs is £696,388.
|jimmy cricket: I am a holder too, but a bit fed up with the declining share price. Perhaps today the corner has been turned, though no £ have been announced.|
|ajrice: At last some good news and the share price responds, albeit modestly.
Not really market manipulation
This happens with thinly traded small cap stocks - market makers don't like to accumulate stock when buying interest seems to disappear (in case of worst case scenario) and walk the price down as long as sellers and buyers are roughly matched.
Until for whatever reason buyers come back in this will continue to fall.
Of course as volumes have been low it wont take that much buying to start reversing the share price losses.|
|ozgem: Correct.It is down on yesterdays close which is what I considered worst case scenario.I am hoping now this will create more upward pressure on the share price as the squeeze will be on to get some of these and eliminate the large spread that puts some investors off the 1 penny shares.|
|bingobarnes: Only just recently started following this share since the two articles in Shares Magazine a while back.
The spread is a whopping 18%. Would I be right in assuming that the spread will come down considerably following the 1 for 25 consolidation?
If so I guess I have to work out whether the increase in share price before consolidation (if any) will be greater than the % of spread saved by waiting till after consolidation. Anyone who's been following this longer got any views this?
|james t kirk: ozgem, yes correct, you will automatically see your holding reduce to 1/25th in number of shares so 25000 shares becomes 1000 new shares.
Out of interest I have just looked at trades since Xmas and at a very rough guess the buys are 4.7m shares and the sells 1.8m. This is still small change when there are 695m shares currently but shows the heavy weighting towards buys.
With all the aquisitions last year and the current one, Cytomyx is becoming a major player and is receiving a good re-rating. I personally can't belive PRM's share price and valuation which seems like fantasy time. With CYX valued at 11.5m which will become 15m soon after the double placing, there could be huge upside. And don't forget this has products which sell and make a profit, so it's a different league to PRM.|
|james t kirk: I reckon the rise is due to the belief that the takeover of Clinomics has been well received, especially as a profit making organisation. The combined companies will be a more powerful force in very similar markets and increased geographical reach for both companies products.
The consolidation will bring the share price to around 40p, which is a more sensible price than 1.5p and will hopefully be taken more seriously by large investment companies.|
|propane: The negative aspect regarding 'consolidations'is that with the resulting higher share price it provides a lot more 'fall' space, as did happen with TGR and i think may happen with cyx.|
|propane: Below is the cyprotex afx, the release coincides about the time of the cyx price increase, ......mix up or not?
AFX-Focus) 2003-09-30 09:00 GMT: Cyprotex says Nordan Holdings takes 29.9 pct stake
LONDON (AFX) - Cyprotex PLC said Nordan Holdings Ltd has acquired 29.9 pct of the company's stock and that it has made significant progress in its development as an ADME focused drug discovery and information company.
Revenue for the 6 months ending 30 June 2003 was 368,804 stg against 329,085 stg for the year earlier.
The operating loss for the first half was 1.077 mln stg against a loss of 1.465 mln the prior year.
"The business has progressed positively in the first half of 2003 and we look forward to building on the technology we have developed and delivering growth in the coming months," it said.
|mashman: The directors of Cytomyx note the recent movement in its share price. The
directors are not aware of any specific reason for the significant share price
movement at this time.|
Cytomyx share price data is direct from the London Stock Exchange